TICKERNERD
Menu
MNOVMNOVHealthcare · Biotechnology

MNOV Stock Forecast: MediciNova, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$1.40
−4.76% on the day

The 4 Wall Street analysts covering MediciNova, Inc. hold a median 12-month price target of $8 — +471.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 28 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$72.4M
Ticker Nerd rank
97/ 100
Median analyst target
$8.00
Analysts covering
4
Revenue$458K+240.6% y/y
Operating income−$2.5M
Net income−$2.3M
Free cash flow−$1.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.7%
1M
−27.1%
YTD
+6.9%
1Y
+18.6%
From 52W high
−59.4%
From 52W low
+18.6%
$1.18
$3.45
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MNOV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores MediciNova, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
97/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
88
Revisions
82
Volatility
82
Size
77
Issuance
77
Accruals
70
Momentum
65
Value
61
Quality
60

Growth (88): Sales and profits are climbing, and climbing faster than before.

Quality (60): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MNOV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MNOV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26MNOVHigh $11.00Median $8.00Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $6.00Median $8.00High $11.00

The green dot is the last close — the median target sits +471.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Sept 2026Roth CapitalInitiatesBuy$6.00
4 May 2026D. Boral CapitalMaintainsBuy$9.00
4 May 2026D. Boral CapitalMaintainsBuy—
23 Mar 2026Maxim GroupReinstatesBuy$6.00
16 Mar 2026HC Wainwright & Co.InitiatesBuy—
30 Jan 2026D. Boral CapitalMaintainsBuy—
18 Dec 2025D. Boral CapitalMaintainsBuy—
8 Dec 2025D. Boral CapitalMaintainsBuy—
4 Nov 2025D. Boral CapitalMaintainsBuy—
31 Oct 2025D. Boral CapitalMaintainsBuy—
22 Sept 2025D. Boral CapitalMaintainsBuy—
27 Aug 2025D. Boral CapitalMaintainsBuy—
24 July 2025D. Boral CapitalMaintainsBuy—
16 June 2025B. Riley SecuritiesMaintainsBuy—
9 Apr 2025D. Boral CapitalMaintainsBuy—
14 Mar 2025D. Boral CapitalMaintainsBuy—
21 Feb 2025D. Boral CapitalMaintainsBuy—
6 Dec 2024D. Boral CapitalMaintainsBuy—
2 Dec 2024D. Boral CapitalInitiatesBuy—
10 Mar 2021Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

MNOV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MNOV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, MediciNova, Inc. returned +18.6% against +13.6% for the S&P 500, dividends included.

MNOV vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250Jan 26Apr 26Jul 26Oct 26MNOVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MNOV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

MediciNova, Inc. (MNOV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.1×

Cheaper than 91% of US stocks

Price / sales
78.1×

Cheaper than 4% of US stocks

Price / book
1.9×

Cheaper than 46% of US stocks

EV / EBITDA
−4.0×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
240.6%

Higher than 96% of US stocks

Earnings growth (YoY)
—
Gross margin
69.3%

Higher than 82% of US stocks

Operating margin
−554.3%

Higher than 7% of US stocks

Net margin
7.6%

Higher than 65% of US stocks

Returns & dividend
Return on equity
−25.6%

Higher than 29% of US stocks

Return on assets
−16.4%

Higher than 22% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

MediciNova, Inc. (MNOV) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • MediciNova, Inc. has a market value of $72.4M and an enterprise value of $47.1M.

  • Revenue in the twelve months to 30 June 2026: $920K. The latest quarter grew 240.6% year on year.

  • Net income over the same four quarters: −$10.8M, a −1168.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$9.1M.

  • Shares outstanding: 49.2M.

  • Trailing P/E: −6.1×; forward P/E: −2.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • MediciNova, Inc. employs 6 people — $153K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

MNOV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
MNOVMediciNova, Inc.$72.4M97
NMRANeumora Therapeutics, Inc.$71.6M33
CGTXCognition Therapeutics, Inc.$71.2M34
MAIAMAIA Biotechnology, Inc.$70.4M27
TENXTenax Therapeutics, Inc.$70.4M18
TELOTelomir Pharmaceuticals, Inc.$74.4M30
CRDFCardiff Oncology, Inc.$69.2M48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own MediciNova, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MNOV news & analysis

MediciNova to Participate in the Maxim Growth Summit

GlobeNewsWire · 6 Oct 2026neutral

MediciNova announced that its management will participate in the Maxim Growth Summit, held October 12-14, 2026, at the Hard Rock Hotel New York. Management will be available for one-on-one meetings with registered investors during the event.

Why it matters — A MNOV watcher would care because participation in the summit gives investors an opportunity to meet management directly and may increase the company's visibility among conference attendees.

MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles

Benzinga · 28 Sept 2026negative

MediciNova reported mixed topline results from its Phase 2 trial of MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes, and the drug fell short on a liver fat parameter. The company's stock was trading lower on Monday following the announcement.

Why it matters — The mixed Phase 2 results, including the shortfall on the liver fat parameter, bear directly on the clinical progress and prospects of MN-001, a key asset in MediciNova's pipeline.

MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

GlobeNewsWire · 28 Sept 2026positive

MediciNova announced topline results from its MN-001-NATG-202 clinical trial of MN-001 (Tipelukast). The treatment showed statistically significant increases in HDL-C and HDL-P, a significant early reduction in triglycerides, a reduction in body weight, and a numerical improvement in liver fat.

Why it matters — The positive topline efficacy results from the MN-001 trial provide MNOV watchers with clinical data on the drug candidate's potential in addressing lipid and metabolic measures.

MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)

GlobeNewsWire · 24 Sept 2026positive

MediciNova announced completion of the last patient, last visit in the double-blind portion of the Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast) for ALS. The trial randomized 234 participants across sites in the US and Canada, with an Open-Label Extension continuing for active participants, and topline results from the double-blind portion expected by the end of 2026.

Why it matters — This milestone brings MediciNova closer to reporting topline efficacy data for its lead ALS candidate, MN-166, which is a key value-determining catalyst for the company.

MediciNova to Participate in Two Investor Conferences in September

GlobeNewsWire · 8 Sept 2026neutral

MediciNova announced that Yuichi Iwaki, M.D. will participate in two investor conferences in September. The company, traded on NASDAQ and the Tokyo Stock Exchange, made the announcement on September 8, 2026.

Why it matters — MNOV watchers would care because investor conference participation offers management a platform to present the company's pipeline and strategy to the investment community, potentially raising visibility.

FAQ

Frequently asked questions about MNOV stock

What is the MNOV stock price forecast for 2026-2027?

The 4 Wall Street analysts covering MediciNova, Inc. have a median 12-month price target of $8, with estimates ranging from $6 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MNOV stock a buy right now?

Of the 4 analysts covering MediciNova, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks MediciNova, Inc. 97 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MNOV?

As at 28 Oct 2026, MediciNova, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (88 of 100).

Will MNOV stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +471.4% from the last close, and Ticker Nerd's factor model ranks MediciNova, Inc. 97 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MNOV stock forecast for 2030?

No analyst covering MediciNova, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MNOV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $11 over the next 12 months.

How has MNOV stock performed over the past year?

MediciNova, Inc. returned +18.6% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does MediciNova, Inc. do?

MediciNova Inc. is a biopharmaceutical company focused on developing novel small-molecule therapeutics for serious diseases with unmet medical needs.

What is the latest news on MNOV?

The most recent item we track (GlobeNewsWire, 6 Oct 2026): "MediciNova to Participate in the Maxim Growth Summit". MediciNova announced that its management will participate in the Maxim Growth Summit, held October 12-14, 2026, at the Hard Rock Hotel New York. Management will be available for one-on-one meetings with registered investors during the event.

Company

About MediciNova, Inc.

MediciNova Inc. is a biopharmaceutical company focused on developing novel small-molecule therapeutics for serious diseases with unmet medical needs. MediciNova’s current programs center on neurology, respiratory disease, and liver-related conditions, with development efforts concentrated on candidates such as MN-166 (ibudilast), MN-001 (tipelukast), and MN-221. Its pipeline targets a range of disorders including neurodegenerative, inflammatory, fibrotic, metabolic, and respiratory diseases, reflecting a portfolio built around differentiated mechanisms of action and clinical development across multiple indications. The company works through strategic alliances and clinical collaborations to advance its programs and support drug development from early research through later-stage trials. Headquartered in La Jolla, California, MediciNova Inc. occupies a specialized role in the biotechnology market by pursuing therapies for complex conditions where current treatment options remain limited.

CEO Dr. Yuichi Iwaki M.D., Ph.D. · 6 employees · United States · https://medicinova.com